NASDAQ · BCTXZ
Healthcare · Biotechnology
$0.25
Down-$0.04 (-15.60%)
Updated Oct 10, 2026, 12:58 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BCTXZ
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
BCTXZ closed at $0.25 after 19 trading sessions, up 73.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $0.25 | $0.25 | $0.25 | $0.25 | 100 |
| Oct 7, 2026 | $0.284 | $0.30 | $0.2293 | $0.2489 | 9.12K |
| Oct 6, 2026 | $0.29 | $0.33 | $0.275 | $0.28 | 8.05K |
| Oct 5, 2026 | $0.2999 | $0.2999 | $0.19 | $0.19 | 744.05 |
| Oct 2, 2026 | $0.2999 | $0.2999 | $0.1844 | $0.298 | 91.51K |
| Oct 1, 2026 | $0.215 | $0.232 | $0.1553 | $0.162 | 30.01K |
| Sep 30, 2026 | $0.1936 | $0.198 | $0.18 | $0.198 | 8.92K |
| Sep 29, 2026 | $0.195 | $0.195 | $0.156 | $0.1836 | 16.7K |
| Sep 28, 2026 | $0.1676 | $0.195 | $0.1676 | $0.195 | 6.12K |
| Sep 25, 2026 | $0.173 | $0.1736 | $0.1403 | $0.1553 | 10.29K |
| Sep 23, 2026 | $0.1806 | $0.215 | $0.1665 | $0.20 | 10.36K |
| Sep 22, 2026 | $0.19 | $0.204 | $0.1713 | $0.20 | 3.41K |
| Sep 21, 2026 | $0.15 | $0.1969 | $0.15 | $0.1969 | 648.18 |
| Sep 18, 2026 | $0.1697 | $0.2647 | $0.1504 | $0.1703 | 10.74K |
| Sep 17, 2026 | $0.1376 | $0.15 | $0.1211 | $0.15 | 30.54K |
| Sep 16, 2026 | $0.1325 | $0.1485 | $0.1325 | $0.1485 | 3.85K |
| Sep 15, 2026 | $0.14 | $0.15 | $0.121 | $0.144 | 47.81K |
| Sep 14, 2026 | $0.13 | $0.1301 | $0.1114 | $0.1301 | 2.25K |
| Sep 11, 2026 | $0.12 | $0.1456 | $0.102 | $0.1441 | 188.87K |
The latest Smart Investors Daily articles mentioning BCTXZ.
Company
Market Activity
Research & News
BCTXZ research
Company profile and research snapshot.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
ChartMill · Sep 21, 2026
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Yahoo · Sep 14, 2026
Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy approachPhase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOB
Yahoo · Sep 8, 2026
Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as “Eleven clinical trials that will shape medicine in 2026” PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering C
Yahoo · Jun 25, 2026
Agreement supports potential commercial readiness for Bria-IMT using Uneedle’s proprietary microneedle technology for intradermal administration Technology is currently used in BriaCell’s pivotal Phase 3 study and is designed to support faster, more convenient administration while enhancing the patient and provider experience Bria-IMT is currently being evaluated in BriaCell’s ongoing pivotal Phase 3 study in advanced metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, June 25
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BCTXZ.
No results
No recent SID articles mention BCTXZ.
